Pipeline Review of Peritoneal Cancer - H2 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 29, 2020--
The “Peritoneal Cancer - Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This latest Pharmaceutical and Healthcare disease pipeline guide Peritoneal Cancer - Pipeline Review, H2 2019, provides an overview of the Peritoneal Cancer (Oncology) pipeline landscape.
Peritoneal cancer is a rare cancer that develops in the peritoneum, a thin, delicate sheet that lines the inside wall of the abdomen and covers the uterus and extends over the bladder and rectum. Peritoneal cancer usually manifests with abdominal distention and diffuse nonspecific abdominal pain secondary to ascites. Peritoneal cancer symptoms may include shortness of breath, rectal bleeding, loss of appetite, frequent urination, constipation, nausea or diarrhea and feeling of fullness, even after a light meal. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.
This Pharmaceutical and Healthcare latest pipeline guide Peritoneal Cancer - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Peritoneal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Peritoneal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 21, 86, 53, 16, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 3 and 8 molecules, respectively.
Peritoneal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Reasons to buy
Key Topics Covered:
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/r3fo1w
View source version on businesswire.com:https://www.businesswire.com/news/home/20200129005424/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH ONCOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2020.
PUB: 01/29/2020 08:10 AM/DISC: 01/29/2020 08:10 AM